Dasa expands partnership with SOPHiA GENETICS for the first decentralized cancer biomarker detection solution in Latin America
Excerpt from the Press Release:
SÃO PAULO, Brazil and BOSTON, Aug. 24, 2021 /PRNewswire/ — Dasa, the largest integrated healthcare network in Brazil, has chosen to expand upon its partnership with SOPHiA GENETICS SA (Nasdaq: SOPH) to offer the first decentralized HRD (Homologous recombination deficiency) analytics solution in Latin America. HRD is a complex biomarker, important for PARP inhibitors, that helps identify whether cancer patients may respond better to specific treatments, and its use could ultimately lead to personalized therapies that benefit the individual patient.
Renowned in Brazil and abroad, Dasa serves more than 20 million patients per year – including approximately 10% of the Brazilian population – through its more than 250,000 medical partners comprised of more than 59 diagnostic medicine brands and hospitals. With the help of the knowledge pooling SOPHiA DDMTM platform, Dasa has drawn further insights upon the many complex molecular datasets that they analyze for the benefit of their patients.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?